- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02173054
An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne
An Evaluator-blind, Randomized, Vehicle-controlled Efficiency of Adjunctive Usage of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel for Improvement of Local Tolerance in Thai Acne Subjects
Acne is an inflammation of sebaceous glands and follicles. Applying topical treatments such as adapalene gel may cause irritant adverse effects. Hence, using a moisturizer is another way to protect or relieve this undesirable event. Moisturizers that have anti-inflammatory property could reduce irritant effects, emergent from using topical treatment and also reduce severity of acne.
Research teams chose an adapalene gel to act as topical treatment for curing acne. It has anti-inflammatory and comedolytic effects and has fewer side effects than other groups of topical retinoic acids. However, peeling skin, redness skin, tingling sensation or itching sensation may occur if they are continually used for a long period. Thus, for the purpose of studying the efficacy of moisturizer containing licochalcone A, L-carnitine and 1,2-decanediol in reducing irritant effect of using adapalene gel (Licochalcone A has anti-inflammatory effect, L-carnitine decrease sebum production and 1,2-decanediol has anti-bacterial effect).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10700
- Siriraj Hospital Mahidol Univeristy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years old or above
- Participants have to control the birth for example, condom method, intrauterine device method before participate in the research at least 1 month until 6 months after research finish.
- being diagnosed acne vulgaris by dermatologist in mild to moderate degree based on Investigators' Global Assessment scale of FDA
Exclusion Criteria:
- Use oral or injected antibiotics or other oral medicine treating acne for example, isotretinoin, oral contraceptives, or spironolactone group during 4 weeks before participate this research
- Have other active skin diseases at face during 2 weeks before participate the research
- Allergic to adapalene gel and moisturizer
- Have severe or uncontrolled underlying diseases
- Getting pregnant or during breast feeding
- Other types of acne(not acne vulgaris)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Adapalene gel
Evening
|
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
Other Names:
|
|
Placebo Comparator: Adapalene gel with placebo moisturizer
Morning
Evening
|
Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
Other Names:
|
|
Active Comparator: Adapalene gel with Eucerin
Morning
Evening
|
Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction of Undesirable Effects
Time Frame: 2nd week, 4th week, and 8th week
|
|
2nd week, 4th week, and 8th week
|
|
Skin Tolerability: Skin Sebum Content and Skin Hydration
Time Frame: Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.
|
Skin tolerability was assessed by measuring the skin surface sebum content, skin hydration with the Sebumeter SM815 and Corneometer CM825, respectively
|
Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.
|
|
Skin Tolerability: Transepidermal Water Loss (TEWL)
Time Frame: Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.
|
Skin tolerability was assessed by measuring TEWL with the Tewameter TM300
|
Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction of Severity of Acne
Time Frame: baseline, 2nd week, 4th week and 8th week
|
|
baseline, 2nd week, 4th week and 8th week
|
|
Reduction of Severity of Acne: Acne Severity Index (ASI)
Time Frame: baseline, 2nd week, 4th week and 8th week
|
|
baseline, 2nd week, 4th week and 8th week
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Acneiform Eruptions
- Sebaceous Gland Diseases
- Acne Vulgaris
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Dermatologic Agents
- Adapalene
Other Study ID Numbers
- Acne and adjuctive moisturizer
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne
-
CLASSYS Inc.Not yet recruitingAcne Scars | Acne Scarring | Acne Scar | Acne Scars - AtrophicChina
-
ProgenaBiomeWithdrawnAcne Vulgaris | Acne | Acne Rosacea | Acne Inversa | Acne Keloidalis | Acne Keloid | Acne Conglobata | Acne Cystic | Acne Pomade | Acne Indurata | Acne Papular | Acne Tropica | Acne Urticata | Acne Fulminans | Acne Follicular | Acne Tropicalis | Acne Detergicans | Acne Iodide | Acne VarioliformisUnited States
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompletedAcne Scar | Acne Scars - AtrophicChina
-
First Affiliated Hospital of Chongqing Medical...CompletedAcne Scars | Acne ScarringChina
-
Technische Universität DresdenUnknown
-
Chulalongkorn UniversityCompletedPost - Adolescence AcneThailand
-
National Yang Ming UniversityTaipei City HospitalUnknown
-
Ulthera, IncCompleted
-
DarierUnknown
-
Sheikh Zayed Medical CollegeCompletedAtrophic Acne Scarring | Atrophic Acne ScarPakistan
Clinical Trials on Adapalene gel
-
Assiut UniversityNot yet recruiting
-
Galderma R&DCompleted
-
Galderma R&DCompleted
-
Aleor Dermaceuticals LimitedCatawba Research, LLCCompletedAcne VulgarisUnited States, Belize
-
Padagis LLCCompleted
-
Galderma R&DCompletedAcneUnited States, Canada, Puerto Rico
-
Galderma R&DCompletedAcne VulgarisAustralia, Belgium, Brazil, France, Germany, Italy, Mexico, Poland, Sweden
-
Actavis Inc.Completed
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico